Y Intercept Hong Kong Ltd Purchases New Shares in TG Therapeutics, Inc. $TGTX

Y Intercept Hong Kong Ltd purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 9,165 shares of the biopharmaceutical company’s stock, valued at approximately $304,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Congress Asset Management Co. acquired a new position in shares of TG Therapeutics during the fourth quarter worth approximately $57,307,000. Man Group plc grew its stake in shares of TG Therapeutics by 621.5% during the third quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after purchasing an additional 868,697 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of TG Therapeutics by 856.6% in the fourth quarter. BNP Paribas Financial Markets now owns 683,653 shares of the biopharmaceutical company’s stock valued at $20,380,000 after purchasing an additional 612,189 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TG Therapeutics by 35.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after purchasing an additional 531,759 shares in the last quarter. Finally, Invesco Ltd. raised its position in TG Therapeutics by 47.1% in the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock worth $47,989,000 after purchasing an additional 515,481 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 2.8%

Shares of NASDAQ TGTX opened at $56.41 on Thursday. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $59.30. The firm has a market capitalization of $8.64 billion, a P/E ratio of 19.72, a P/E/G ratio of 1.41 and a beta of 1.60. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The company’s 50 day simple moving average is $47.27 and its 200 day simple moving average is $36.86.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The business had revenue of $204.92 million for the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.TG Therapeutics’s revenue was up 69.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS. On average, analysts predict that TG Therapeutics, Inc. will post 1.42 EPS for the current year.

Key Headlines Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on TG Therapeutics and maintained a $77 price target, reinforcing a constructive outlook for the shares. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: Analysts raised long-term earnings estimates for FY2028, FY2029, and FY2030, indicating improving confidence in TG Therapeutics’ multi-year growth prospects.
• Neutral Sentiment: HC Wainwright lowered several near-term EPS estimates for 2026 and FY2027, which may temper enthusiasm in the short run but does not change the bullish rating.
• Negative Sentiment: Reduced earnings forecasts for Q2, Q3, Q4 2026 and FY2026 suggest the market may be pricing in some execution risk or slower-than-previously-expected profitability.

Analyst Upgrades and Downgrades

TGTX has been the topic of several research reports. Bank of America upped their price objective on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. HC Wainwright upped their price target on TG Therapeutics from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Monday. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.33.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.